Financials
- Financial year
- 2025
- Total assets
- €135,553
- Loss
- -€19,173
- Solvency
- 96.5%
MYTHRALICA
ActiveSummary
MYTHRALICA has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €130,827 and a net result of -€19,173. Its solvency ranks better than 93% of 73 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21209
1 site
Size
€135,553total assets 2025
- Equity
- €130,827
- Loss
- -€19,173
Turnover not published (micro format)
Structure
- Largest shareholder
- Toucan Health Innovations · 20%
Accounts 29 days early
Why 96raises riskLoss of €19,173 (financial year 2025)lowers riskLiquidity: current ratio 24.38, cash €90,600Equity €130,827 (96.5% of total assets)Size: total assets €135,553Show the evidence
Checked score
Score 2025
96
/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 70% of its sector peers (NACE 21, micro)
Financial strength
Strong
Solvency
100
equity 96.5% of total assets
Liquidity
100
short-term debt 2.7% · cash 66.8%
Profitability
1
return on assets -14.1%
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
06-2026: 1.3%highest value
07-2026: 1.3%● unchanged vs 06-2026highest value
08-2026: 0.1%▼ -1.2 percentage points vs 07-2026lowest value
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
Credit of up to €12,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Liquidity ample (current ratio 24.38, above the usual 1.5; short-term debt: 2.7% and cash: 66.8% of total assets), and 3.5% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro): better than 90% on solvency, 96% on liquidity and 25% on profitability.
The bankruptcy probability was computed on 18-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Young company
Founded in 2025, a year ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-07-2026, 29 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
29 days early
← before the deadline
after the deadline →
Searched, nothing found (1)
- Annual accounts filedfinancial year 2025 · micro…
- IncorporationAppointment: ANDREEVA Tatyana Vladiminirovna (director)…
Key points
By topic
Board & ownership
- Largest shareholder
- Toucan Health Innovations · 20%
Timeline
- Events
- 2
- Since
- 2025
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21209
- Founded
- 20-05-2025
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 31
- Purpose
- “La fabrication,le traitement,l’importation,l’exportation,l’achat,la vente,la…” (deed in French)
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark Roughly what is this company worth?Value indication
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.